Meritain Health policies, page 2

Search Meritain Health's public medical, payment and drug policies by CPT or HCPCS code, keyword or policy number, with links to the payer's own documents. Links open the payer's own document; check its current version before relying on it.

106 policies name 96365, those listing the fewest codes first. A policy that names a code may also list it as excluded.

Meritain Health policies
PolicyDetailsCodesSource
0939-Transthyretin-Mediated (ATTR) Amyloidosis0939 · Commercial25Original policy ↗
1099-Narsoplimab-wuug (Yartemlea)1099 · Commercial25Original policy ↗
0751-Natalizumab0751 · Commercial26Original policy ↗
1060-Fidanacogene Elaparvovec-dzkt (Beqvez)1060 · Commercial27Original policy ↗
0884-Siltuximab (Sylvant)0884 · Commercial28Original policy ↗
0946-Ravulizumab-cwvz (Ultomiris)0946 · Commercial28Original policy ↗
1013-Spesolimab-sbzo (Spevigo)1013 · Commercial28Original policy ↗
Intravenous Iron Therapy0575 · Commercial28Original policy ↗
Trastuzumab Products0313 · Commercial28Original policy ↗
0915-Nusinersen (Spinraza)0915 · Commercial30Original policy ↗
1058-Atidarsagene Autotemcel (Lenmeldy)1058 · Commercial30Original policy ↗
0810-Gout0810 · Commercial34Original policy ↗
1037-Valoctocogene Roxaparvovec-rvox (Roctavian) - CPB 10361037 · Commercial35Original policy ↗
Pegzilarginase-nbln (Loargys)1101 · Commercial35Original policy ↗
Pemetrexed Products0687 · Commercial35Original policy ↗
0845-Carfilzomib (Kyprolis)0845 · Commercial38Original policy ↗
0907-Reslizumab (Cinqair)0907 · Commercial38Original policy ↗
0997-Anifrolumab-fnia (Saphnelo)0997 · Commercial38Original policy ↗
0024-Aldesleukin (Proleukin)0024 · Commercial39Original policy ↗
0905-Secukinumab (Cosentyx)0905 · Commercial39Original policy ↗
0544-Immune Globulins for Post-exposure Prophylaxis0544 · Commercial41Original policy ↗
1023-Etranacogene Dezaparvovec-drlb (Hemgenix)1023 · Commercial41Original policy ↗
1002-Efgartigimod Alfa-fcab (Vyvgart) and Efgartigimod Alfa and Hyaluronidase-qvfc (Vyvgart Hytrulo)1002 · Commercial42Original policy ↗
1017-Elivaldogene Autotemcel (Skysona)1017 · Commercial44Original policy ↗
0818-Belimumab (Benlysta)0818 · Commercial47Original policy ↗
Human Fibrinogen Concentrate Products0792 · Commercial49Original policy ↗
0975-Inebilizumab-cdon (Uplizna)0975 · Commercial50Original policy ↗
Headaches: Nonsurgical Management0462 · Commercial50Original policy ↗
0885-Vedolizumab (Entyvio)0885 · Commercial52Original policy ↗
0978-Lurbinectedin (Zepzelca)0978 · Commercial53Original policy ↗
0892-Nivolumab Products (Opdivo, Opdivo Qvantig, and Opdualag)0892 · Commercial58Original policy ↗
0912-Ustekinumab0912 · Commercial61Original policy ↗
Breast Biopsy Procedures0269 · Commercial61Original policy ↗
0953-Onasemnogene Abeparvovec (Zolgensma and Itvisma)0953 · Commercial62Original policy ↗
Abatacept (Orencia)0720 · Commercial64Original policy ↗
Clotting Factors0131 · Commercial64Original policy ↗
Injectable Medications0020 · Commercial64Original policy ↗
1009-Risankizumab-rzaa (Skyrizi)1009 · Commercial66Original policy ↗
Kidney Transplantation0493 · Commercial68Original policy ↗
Alopecia Areata0423 · Commercial72Original policy ↗
Golimumab (Simponi and Simponi Aria)0790 · Commercial74Original policy ↗
Lysosomal Storage Disorder Treatments0442 · Commercial76Original policy ↗
Lyme Disease and other Tick-Borne Diseases0215 · Commercial80Original policy ↗
0799-Tocilizumab0799 · Commercial81Original policy ↗
Post-Herpetic Neuralgia0725 · Commercial87Original policy ↗
Trigeminal Neuralgia: Treatments0374 · Commercial88Original policy ↗
Hematopoietic Colony-Stimulating Factors (CSFs)0055 · Commercial91Original policy ↗
Infliximab0341 · Commercial92Original policy ↗
0729-Diabetic Neuropathy: Selected Treatments0729 · Commercial94Original policy ↗
Parenteral Immunoglobulins0206 · Commercial107Original policy ↗

Back to Meritain Health

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.